背景:FleischnerSociety建立了2019年冠状病毒病患者成像共识指南(COVID-19)。我们根据患者的症状和危险因素分组,调查了肺炎的患病率和不良结局,并评估了Fleischner学会影像学指南在评估COVID-19患者胸部X光片方面的适用性。
方法:2020年2月至2020年5月,685例患者(204例男性,平均58±17.9年),包括诊断为COVID-19并住院的患者。我们根据症状的严重程度和危险因素的存在(年龄>65岁和合并症的存在)将患者分为四组。患者组定义如下:第1组(无症状患者),第2组(症状轻微,无危险因素的患者),第3组(症状和危险因素较轻的患者),和第4组(有中度至重度症状的患者)。根据Fleischner协会的说法,第1-2组未显示胸部成像,但第3-4组未显示胸部成像.我们比较了胸片上肺炎的患病率和评分,并比较了不良结局(进展为重症肺炎,重症监护室入院,和死亡)群体之间。
结果:在685例COVID-19患者中,138(20.1%),396(57.8%),102(14.9%),49例(7.1%)患者分别对应于第1至第4组。第3-4组患者年龄明显较大,肺炎患病率明显较高(第1-4组:37.7%,51.3%,71.6%,98%,分别,P<0.001)比第1-2组。3-4组的不良结局也高于1-2组(1-4组:8.0%,3.5%,6.9%,51%,分别,P<0.001)。第1组不良结局患者最初无症状,但在随访期间出现症状。他们年龄较大(平均年龄,80岁),其中大多数有合并症(81.8%)。一致无症状的患者没有不良事件。
结论:根据COVID-19患者的症状和危险因素,肺炎的患病率和不良结局不同。因此,正如弗莱施纳协会建议的那样,对于有合并症的有症状的老年患者,使用胸片评估和监测COVID-19肺炎是必要的.
BACKGROUND: The Fleischner Society established
consensus guidelines for imaging in patients with coronavirus disease 2019 (COVID-19). We investigated the prevalence of pneumonia and the adverse outcomes by dividing groups according to the symptoms and risk factors of patients and assessed the suitability of the Fleischner society imaging
guidelines in evaluating chest radiographs of COVID-19 patients.
METHODS: From February 2020 to May 2020, 685 patients (204 males, mean 58 ± 17.9 years) who were diagnosed with COVID-19 and hospitalized were included. We divided patients into four groups according to the severity of symptoms and presence of risk factors (age > 65 years and presence of comorbidities). The patient groups were defined as follows: group 1 (asymptomatic patients), group 2 (patients with mild symptoms without risk factors), group 3 (patients with mild symptoms and risk factors), and group 4 (patients with moderate to severe symptoms). According to the Fleischner society, chest imaging is not indicated for groups 1-2 but is indicated for groups 3-4. We compared the prevalence and score of pneumonia on chest radiographs and compare the adverse outcomes (progress to severe pneumonia, intensive care unit admission, and death) between groups.
RESULTS: Among the 685 COVID-19 patients, 138 (20.1%), 396 (57.8%), 102 (14.9%), and 49 (7.1%) patients corresponded to groups 1 to 4, respectively. Patients in groups 3-4 were significantly older and showed significantly higher prevalence rates of pneumonia (group 1-4: 37.7%, 51.3%, 71.6%, and 98%, respectively, P < 0.001) than those in groups 1-2. Adverse outcomes were also higher in groups 3-4 than in groups 1-2 (group 1-4: 8.0%, 3.5%, 6.9%, and 51%, respectively, P < 0.001). Patients with adverse outcomes in group 1 were initially asymptomatic but symptoms developed during follow-up. They were older (mean age, 80 years) and most of them had comorbidities (81.8%). Consistently asymptomatic patients had no adverse events.
CONCLUSIONS: The prevalence of pneumonia and adverse outcomes were different according to the symptoms and risk factors in COVID-19 patients. Therefore, as the Fleischner Society recommended, evaluation and monitoring of COVID-19 pneumonia using chest radiographs is necessary for old symptomatic patients with comorbidities.